Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Alterity Therapeutics Ltd
  6. News
  7. Summary
       AU000000PBT9

ALTERITY THERAPEUTICS LTD

SummaryChartsNewsRatingsCalendarCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Prana Biotechnology : EGM and Conference Call Facility

03/26/2019 | 11:45pm EST

Prana Biotechnology (ASX: PBT, NASDAQ PRAN) today advises that a conference call facility will be available at the Extraordinary General Meeting (EGM) scheduled for Friday, April 5, 2019, at 11:00 AM AEDT.

Shareholders will vote on the transaction with Boston based Life Biosciences LLC and the appointment of Dr David Sinclair and Mr Tristan Edwards on the Board of Directors. In addition, shareholders will also vote on a change of name to Alterity Therapeutics Limited and ratification of prior issue of shares.

Shareholders can pre-register at the link below:

https://services.choruscall.com.au/diamondpass/prana-167745-invite.html

If you are unable to use the 'Register Now' button above, then at the time of the conference you can call one of the numbers below and provide the conference ID 167745 to an operator.

Australia Toll Free:

1 800 558 698

Alternate Australia Toll Free:

1 800 809 971

Australia Local:

02 9007 3187

Singapore:

800 101 2785

Hong Kong:

800 966 806

United States:

(855) 881 1339

US Local (New York):

(914) 202 3258

US Local (Los Angeles):

(909) 235 4020

US Local (Chicago):

(815) 373 2080

Disclaimer

Prana Biotechnology Ltd. published this content on 27 March 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 27 March 2019 04:44:10 UTC


ę Publicnow 2019
All news about ALTERITY THERAPEUTICS LTD
01/06Alterity Therapeutics Wins US Patent to Develop Treatments for Neurodegenerative Disord..
MT
01/06Wall Street Set for Mixed Open After Fed-Induced Retreat
MT
01/06Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Disease..
CI
01/06ALTERITY THERAPEUTICS : Granted New US Patent for Compounds for Neurodegenerative Diseases..
PU
01/05Alterity Therapeutics Jumps 20% After Securing Patent for Compounds to Treat Neurodegen..
MT
01/05ALTERITY THERAPEUTICS : Final Director's Interest Notice - Form 6-K
PU
01/05ALTERITY THERAPEUTICS : to Present at the H.C. Wainwright BIOCONNECT Virtual Conference - ..
PU
01/05ALTERITY THERAPEUTICS : Notification of cessation of securities - ATH - Form 6-K
PU
01/04ALTERITY THERAPEUTICS : Announces Resignation of Non-Executive Directors - Form 6-K
PU
01/04Alterity Therapeutics Limited Announces Resignation of David Sinclair as Non-Executive ..
CI
More news
Analyst Recommendations on ALTERITY THERAPEUTICS LTD
More recommendations
Chart ALTERITY THERAPEUTICS LTD
Duration : Period :
Alterity Therapeutics Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
David A. Stamler Chief Executive Officer
Kathryn J. E. Andrews Chief Financial Officer
Geoffrey Paul Kempler Non-Executive Chairman
Brian Derek Meltzer Independent Non-Executive Director
Peter Ashley Marks Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ALTERITY THERAPEUTICS LTD48.48%36
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%53 950
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684